These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 26864303)
1. Basics of PD-1 in self-tolerance, infection, and cancer immunity. Chikuma S Int J Clin Oncol; 2016 Jun; 21(3):448-55. PubMed ID: 26864303 [TBL] [Abstract][Full Text] [Related]
2. Coinhibitory Pathways in Immunotherapy for Cancer. Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206 [TBL] [Abstract][Full Text] [Related]
3. T cell checkpoint regulators in the heart. Grabie N; Lichtman AH; Padera R Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the clinical development of immune checkpoint blockade therapy. Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647 [TBL] [Abstract][Full Text] [Related]
5. New checkpoints in cancer immunotherapy. Ni L; Dong C Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699 [TBL] [Abstract][Full Text] [Related]
6. A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Guram K; Kim SS; Wu V; Sanders PD; Patel S; Schoenberger SP; Cohen EEW; Chen SY; Sharabi AB Front Immunol; 2019; 10():491. PubMed ID: 30936880 [TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibition in ovarian cancer. Hamanishi J; Mandai M; Konishi I Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470 [TBL] [Abstract][Full Text] [Related]
10. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. van Dam LS; de Zwart VM; Meyer-Wentrup FA Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979 [TBL] [Abstract][Full Text] [Related]
11. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Chen J; Jiang CC; Jin L; Zhang XD Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673 [TBL] [Abstract][Full Text] [Related]
12. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. Wang Y; Wu L; Tian C; Zhang Y Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997 [TBL] [Abstract][Full Text] [Related]
13. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912 [TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587 [TBL] [Abstract][Full Text] [Related]
15. Treg-mediated acquired resistance to immune checkpoint inhibitors. Saleh R; Elkord E Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738 [TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
17. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Furness AJ; Quezada SA; Peggs KS Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975 [No Abstract] [Full Text] [Related]
18. [The "immune checkpoints", how does it work]. Granier C; Soumelis V; Mandavit M; Gibault L; Belazzoug R; de Guillebon E; Badoual C; Tartour E; Roussel H Ann Pathol; 2017 Feb; 37(1):18-28. PubMed ID: 28160999 [TBL] [Abstract][Full Text] [Related]